CHC Healthcare Group announced on the 11th that its pharmacy chain brand Fukang Pharmacy is planning to expand into central and southern Taiwan between 2025 and 2026. Over the next three years, in addition to ongoing branch expansion, the company will focus on four key strategic pillars: deepening engagement with the National Health Insurance (NHI) channel, extending pharmaceutical services into long-term care, developing a new channel for pet healthcare, and integrating digital health solutions. The goal is to submit an IPO application by 2026.
CHC noted that amid renewed consolidation in the pharmacy industry, several previously high-profile M&A cases have reportedly progressed slower than expected. As the market closely watches the evolving competitive landscape of Taiwan’s retail pharmacy sector, Fukang Pharmacy has publicly expressed strong confidence in the industry and reaffirmed its commitment to steady, long-term development.
Fukang currently operates 60 locations across Taiwan, with most concentrated in the Taipei and New Taipei area. The company is set to enter the Hsinchu market by the end of 2024 and continues to see steady growth in both store count and revenue. Its expansion into central and southern Taiwan is scheduled to begin in 2025. Alongside this regional push, the company will concentrate on its four-pronged strategy: strengthening NHI engagement, expanding pharmaceutical support for long-term care, launching a new pet wellness channel, and advancing digital healthcare integration, all with the objective of completing its IPO filing by 2026.
Fukang emphasized that industry consolidation is a natural progression, but “stability, team strength, and customer trust are the true foundations of long-term success.” In response to growing concerns around pharmacist workforce shortages, Fukang has proactively implemented strategies for talent attraction and development. These include establishing an internal career advancement roadmap for district supervisors, building a comprehensive succession plan, offering educational subsidies and relocation support for pharmacists, and increasing opportunities for cross-functional project participation to foster a sense of professional achievement.
The company also observed that amid the consolidation wave, many pharmacists and operational talents with vision and ambition are injecting transformative energy into the sector. Fukang welcomes like-minded partners to join its mission, stressing that “people are the most critical investment in Fukang’s growth.”
Fukang added, “We believe that maintaining stability during times of industry turbulence is a rare and valuable strength.” In Q3 of this year, the company will launch a “Strategic Investor and Regional Channel Partner Dialogue Program,” opening up opportunities for synergistic partnerships and strategic investments to support its three-year expansion and revenue growth plan in central and southern Taiwan, as well as within the long-term care channel.
Resource: 持續看好藥局商機 承業醫子公司富康拚明年申請IPO
